Inside Peptides
Search
Menu

Survodutide vs Semaglutide: Comparing the Evidence

Semaglutide activates the GLP-1 receptor and is an approved medicine with cardiovascular and kidney outcome data. Survodutide adds glucagon-receptor activity, has completed phase 3 weight trials and is not approved. The only randomized trial including both was a 16-week phase 2 study in type 2 diabetes with an open-label semaglutide group.

Investigational FDA Approved Short phase 2 comparison only
Comparison banner for survodutide, an investigational glucagon and GLP-1 dual agonist, and semaglutide, an approved GLP-1 receptor agonist.
Survodutide adds glucagon-receptor activity to the GLP-1 receptor activity it shares with semaglutide. Illustration © Inside Peptides.
Evidence-Based Short Answer

Evidence-Based Summary

The only randomized data with both drugs come from a 16-week phase 2 trial in 413 adults with type 2 diabetes. HbA1c fell about the same with a lower survodutide dose and with semaglutide (−1.46 vs −1.47 percentage points); higher survodutide doses lowered weight more (up to −8.7% vs −5.3% with semaglutide), but adverse events, mainly gastrointestinal, were more common (77.8% vs 52.0%). The semaglutide group was open-label and the trial was not designed as a formal head-to-head test. In separate phase 3 obesity trials, survodutide groups lost 12.2% and 13.0% of body weight over 76 weeks (placebo 5.4%), and semaglutide 14.9% over 68 weeks (placebo 2.4%); these figures are from different trials and not directly comparable. Semaglutide is approved and has proven cardiovascular benefit; survodutide does not yet have published outcome results.

Medical disclaimer: Inside Peptides provides educational, evidence-first scientific analysis. Survodutide is not an approved medicine, and FDA has warned companies selling it as a "research" product. Treatment decisions belong with a qualified clinician. We do not provide treatment recommendations.
At a Glance

Quick Comparison: Survodutide vs Semaglutide

A high-level comparison of molecule class, molecular receptor targets, FDA regulatory approvals, and verified clinical programs.

Table 1: Verified regulatory, pharmacological, and clinical comparison between Survodutide and Semaglutide.
Feature Survodutide Semaglutide
Class Investigational glucagon/GLP-1 dual agonist Approved GLP-1 receptor agonist
Target receptors Glucagon and GLP-1 receptors GLP-1 receptor
How it is given Once-weekly injection under the skin, in trials Once-weekly injection or daily tablet, depending on product
U.S. regulatory status (October 2026) Not FDA-approved; FDA has warned sellers of unapproved "research" survodutide FDA-approved in several products for type 2 diabetes, weight management and defined cardiovascular, kidney and liver indications
Strongest human evidence Phase 3 placebo-controlled weight trials; phase 2 biopsy trial in MASH Phase 3 trials plus cardiovascular (SELECT) and kidney (FLOW) outcome trials
Main safety concerns Very frequent gastrointestinal effects (80.9%–89.7% in SYNCHRONIZE-1) Gastrointestinal effects; label warnings including pancreatitis and gallbladder disease, and a boxed warning based on rodent thyroid C-cell tumors
Direct comparison 16-week phase 2 trial in type 2 diabetes (semaglutide arm open-label) Same trial
WADA status (2026 List) Not named; as a drug with no regulatory approval it may fall under S0 (non-approved substances) Not named on the 2026 Prohibited List
Receptor Biology

Adding Glucagon to GLP-1

GLP-1 receptor activation lowers appetite and supports insulin release. Glucagon receptor activation raises energy expenditure and fat burning in the liver but can raise blood glucose; pairing it with GLP-1 activity is meant to balance that.

Survodutide Target

Survodutide

Primary Target: Glucagon and GLP-1 receptors

Affinity Profile: Dual agonist; acylated (fatty-acid chain) for weekly action

In mice, survodutide reduced body weight more than semaglutide by both lowering food intake and raising energy expenditure. These are animal results; a human PET study comparing liver glucagon-receptor activity with semaglutide is still running.

Semaglutide Target

Semaglutide

Primary Targets: GLP-1 receptor

Affinity Profile: Selective GLP-1 receptor agonist

Supports glucose-dependent insulin release, lowers glucagon and reduces food intake.

Regulatory Status

FDA Status: Approved Medicine vs Investigational Drug

United States status checked 10–11 October 2026.

Investigational

Survodutide Status & Formulations

Not FDA-approved; no record appears in Drugs@FDA or DailyMed. FDA reports it has warned companies illegally selling unapproved survodutide falsely labelled "for research purposes" or "not for human consumption".

FDA Approved

Semaglutide Status & Formulations

Ozempic injection covers type 2 diabetes and specified cardiovascular and kidney risk indications. Rybelsus and Ozempic tablets have their own diabetes and cardiovascular indications. Wegovy injection and tablets cover defined weight and cardiovascular indications; injectable Wegovy's adult MASH indication (F2–F3 fibrosis) is an accelerated approval with confirmatory requirements.

Critical Regulatory Distinction

Both drugs are being studied in MASH (fatty liver disease with inflammation). Semaglutide has an accelerated approval for a defined MASH population; survodutide's phase 3 MASH trial is recruiting.

Clinical Evidence

SYNCHRONIZE vs STEP, and One Direct Phase 2 Trial

Most evidence for each drug is placebo-controlled. Placebo-controlled results from different trials are not directly comparable; the phase 2 diabetes trial is the only one that randomized people to both.

Survodutide: Clinical Evidence Overview

SYNCHRONIZE-1 (725 adults with obesity without diabetes, 76 weeks): −12.2% and −13.0% vs −5.4% with placebo. SYNCHRONIZE-2 (752 adults with obesity and type 2 diabetes, 76 weeks): −8.2% and −9.8% vs −3.9%; HbA1c −0.9 and −0.8 vs −0.2 points. In the phase 2 diabetes trial with a semaglutide group (413 adults, 16 weeks), HbA1c fell 0.91 to 1.71 points across survodutide groups and weight up to 8.7%. Funded by Boehringer Ingelheim.

Semaglutide: Clinical Evidence Overview

STEP 1 (1,961 adults with overweight or obesity without diabetes, 68 weeks): −14.9% vs −2.4% with placebo. STEP 2 (1,210 adults with type 2 diabetes, 68 weeks): −9.6% vs −3.4%. SELECT: major cardiovascular events 6.5% vs 8.0% with placebo (HR 0.80). In the 16-week phase 2 trial, open-label semaglutide lowered HbA1c 1.47 points and weight 5.3%. Funded by Novo Nordisk (STEP, SELECT).

Evidence Matrix

Curated Clinical Evidence Table

A curated selection of the primary studies behind each compound’s evidence profile. Results from different studies are not directly comparable.

Table 3: Key studies evaluating Survodutide and Semaglutide.
Study & Citation Population Comparison & Dosing Duration Main Endpoint Key Finding Methodological Limitations
Survodutide phase 2 with semaglutide arm (Blüher et al., Diabetologia 2024) 413 adults with type 2 diabetes on metformin Six survodutide regimens vs placebo (double-blind) vs semaglutide (open-label) 16 weeks HbA1c change; weight change (key secondary) HbA1c: lower survodutide dose −1.46 vs semaglutide −1.47 points. Weight: higher survodutide doses beat semaglutide (up to −8.7% vs −5.3%). Adverse events 77.8% vs 52.0%. Short; semaglutide open-label and not the comparator for a formal superiority test; no p-values for survodutide vs semaglutide in the abstract.
SYNCHRONIZE-1 (le Roux et al., NEJM 2026) 725 adults with obesity, without diabetes Survodutide (two dose groups) vs placebo 76 weeks Percent change in body weight (treatment-regimen estimand) −12.2% and −13.0% vs −5.4% with placebo. Gastrointestinal events 80.9% and 89.7% vs 47.9%.
SYNCHRONIZE-2 (Wharton et al., NEJM 2026) 752 adults with obesity and type 2 diabetes Survodutide (two dose groups) vs placebo 76 weeks Percent change in body weight −8.2% and −9.8% vs −3.9% with placebo. Different trial from STEP 2; not directly comparable.
STEP 1 (Wilding et al., NEJM 2021) 1,961 adults with overweight or obesity, without diabetes Weekly injectable semaglutide vs placebo 68 weeks Percent change in body weight −14.9% vs −2.4% with placebo. Different trial, length and analysis from SYNCHRONIZE-1.
STEP 2 (Davies et al., Lancet 2021) 1,210 adults with overweight or obesity and type 2 diabetes Weekly injectable semaglutide vs placebo 68 weeks Percent change in body weight −9.6% vs −3.4% with placebo. Different trial from SYNCHRONIZE-2.
SELECT (Lincoff et al., NEJM 2023) 17,604 adults with cardiovascular disease and overweight or obesity, no diabetes Weekly injectable semaglutide vs placebo Mean 39.8 months Cardiovascular death, heart attack or stroke 6.5% vs 8.0%; HR 0.80 (95% CI 0.72–0.90). No published survodutide outcome result to compare.
Safety & Tolerability

Tolerability: More Gastrointestinal Effects With Survodutide in Trials

Semaglutide's safety profile is in FDA labels backed by years of use. Survodutide's comes from trials; in the one trial with both drugs, adverse events were more frequent with survodutide.

Boxed Warning

Semaglutide only: Boxed Warning for thyroid C-cell tumors

Semaglutide labels carry a boxed warning because thyroid C-cell tumors occurred in rodents; whether this happens in humans is unknown. Survodutide has no FDA label, so no labelled warnings exist for it; that is not evidence that it is safer.

Table 4: Evidence-supported safety considerations and adverse-reaction frequency for Survodutide and Semaglutide.
Safety Consideration Survodutide Semaglutide
Adverse events in the direct phase 2 trial 77.8%, mainly gastrointestinal 52.0% (placebo 52.5%)
Gastrointestinal events in phase 3 obesity trials SYNCHRONIZE-1: 80.9% and 89.7% vs 47.9% with placebo STEP 1: nausea and diarrhoea most common; 4.5% stopped for gastrointestinal events vs 0.8%
Label warnings None (no FDA label) Pancreatitis, gallbladder disease, dehydration-related kidney injury, hypoglycemia with insulin or an insulin secretagogue
Long-term outcome data SYNCHRONIZE-CVOT completed on the registry; results not yet published SELECT and FLOW outcome trials completed
Pharmacological Commonalities

What Survodutide and Semaglutide Have in Common

Where the two compounds overlap in biology, evidence or regulatory context.

GLP-1 receptor activity

Both activate the GLP-1 receptor and are given as weekly injections.

Liver disease interest

Both are being developed for MASH; semaglutide has an accelerated approval in a defined group.

Gastrointestinal side effects

Nausea, diarrhoea and vomiting are the most common side effects of both.

Distinguishing Features

Key Scientific & Clinical Differences

Meaningful distinctions in mechanism, strength of evidence, safety and regulatory status.

Glucagon receptor

Survodutide also activates the glucagon receptor; semaglutide does not.

Approval and outcomes

Semaglutide is FDA-approved with cardiovascular and kidney outcome data; survodutide is investigational.

Tolerability

In the direct phase 2 trial and in phase 3, survodutide had high rates of gastrointestinal adverse events.

Inside Peptides Editorial Policy

Scientific Comparison vs Clinical Recommendations

Inside Peptides compares scientific evidence, receptor pharmacology, and official regulatory documents to advance public and professional understanding. We do not determine which compound is appropriate for an individual patient, rank medications with arbitrary scores, or recommend initiating or switching treatments.

Decisions about any medicine require a licensed healthcare professional who can weigh personal medical history, contraindications, interactions and monitoring needs. Unapproved peptides have no established safe use, and products sold as “research chemicals” are not the preparations studied in clinical research.

Evidence Verification

Approved Uses vs Online Claims

A critical scientific distinction between verified, FDA-approved clinical uses and unverified claims circulating on social media and vendor platforms.

Survodutide causes more weight loss than semaglutide

Unproven
Regulatory Context:

Survodutide is not FDA-approved.

Scientific Reality:

In one 16-week diabetes trial, higher survodutide doses lowered weight more than open-label semaglutide, but the trial was short and not built for that comparison. Phase 3 figures come from separate trials and are not directly comparable.

Survodutide is better for fatty liver than semaglutide

Unproven
Regulatory Context:

Injectable Wegovy has an accelerated MASH approval for a defined adult population; survodutide has none.

Scientific Reality:

Survodutide showed liver benefit versus placebo in a phase 2 biopsy trial, but no trial has compared it with semaglutide for liver outcomes.

Claim-Level Certainty

Evidence Strength Across Clinical Domains

Inside Peptides evaluates scientific certainty at the claim level. Because clinical evidence varies significantly depending on the therapeutic endpoint evaluated, each domain is assessed independently.

Weight reduction in adults with obesity

Survodutide has two positive phase 3 trials; semaglutide has multiple phase 3 trials and approval.

Survodutide: Moderate Evidence
Semaglutide: Strong Evidence

Glucose control in type 2 diabetes

Survodutide lowered HbA1c in phase 2 and phase 3; semaglutide is approved for type 2 diabetes.

Survodutide: Moderate Evidence
Semaglutide: Strong Evidence

Cardiovascular outcomes

SELECT showed benefit with semaglutide; survodutide's cardiovascular trial has not been published.

Survodutide: Insufficient Evidence
Semaglutide: Strong Evidence

Survodutide vs semaglutide directly

One 16-week phase 2 trial with an open-label semaglutide arm.

Survodutide: Early Human Evidence
Semaglutide: Early Human Evidence
Unresolved Questions

What Research Still Doesn’t Tell Us

Identifying open scientific questions, pending active-comparator trials, and areas where long-term clinical data remain incomplete.

A proper head-to-head trial

No phase 3 trial comparing survodutide with semaglutide was found in the registry search for this page.

Cardiovascular safety

SYNCHRONIZE-CVOT is listed as completed but its results are unpublished.

Human mechanism

A phase 1 PET study is comparing liver glucagon-receptor occupancy with semaglutide; it is active, not recruiting.

Liver outcomes

Survodutide's phase 3 MASH trial (LIVERAGE) is recruiting.

Related Compound Profiles

Individual profiles provide full molecular datasheets, CAS numbers, preclinical histories, and compound monographs.

Bibliography & Sources

Scientific & Regulatory References

Every pharmacological mechanism, clinical trial result, and regulatory approval cited on this page is traceable to official FDA prescribing documentation, ClinicalTrials.gov registries, or peer-reviewed medical publications.

  1. Phase 2 randomized controlled trial · Open-label active arm
    Dose-response effects on HbA(1c) and bodyweight reduction of survodutide, a dual glucagon/GLP-1 receptor agonist, compared with placebo and open-label semaglutide in people with type 2 diabetes: a randomised clinical trial
    Blüher M et al. (2024) · Diabetologia.
    Phase 2, registered on ClinicalTrials.gov; funded by Boehringer Ingelheim. A published correction exists.
    Direct Source DOI: 10.1007/s00125-023-06053-9 PubMed: 38095657
  2. Phase 3 randomized controlled trial
    Survodutide Once Weekly for the Treatment of Adults with Obesity
    le Roux CW et al. (2026) · N Engl J Med.
    Direct Source DOI: 10.1056/NEJMoa2600751 PubMed: 42253238
  3. Phase 3 randomized controlled trial
    Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes
    Wharton S et al. (2026) · N Engl J Med.
    Direct Source DOI: 10.1056/NEJMoa2607219 PubMed: 42820639
  4. Phase 2 randomized controlled trial
    A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis
    Sanyal AJ et al. (2024) · N Engl J Med.
    Direct Source DOI: 10.1056/NEJMoa2401755 PubMed: 38847460
  5. Preclinical study
    BI 456906: Discovery and preclinical pharmacology of a novel GCGR/GLP-1R dual agonist with robust anti-obesity efficacy
    Zimmermann T et al. (2022) · Mol Metab.
    Cell and mouse data.
    Direct Source DOI: 10.1016/j.molmet.2022.101633 PubMed: 36356832
  6. Phase 3 randomized controlled trial
    Once-Weekly Semaglutide in Adults with Overweight or Obesity
    Wilding JPH et al. (2021) · N Engl J Med.
    Direct Source DOI: 10.1056/NEJMoa2032183 PubMed: 33567185
  7. Phase 3 randomized controlled trial
    Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
    Davies M et al. (2021) · Lancet.
    Article title reproduced as published; it is not dosing guidance.
    Direct Source DOI: 10.1016/S0140-6736(21)00213-0 PubMed: 33667417
  8. Cardiovascular outcomes trial
    Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
    Lincoff AM et al. (2023) · N Engl J Med.
    Direct Source DOI: 10.1056/NEJMoa2307563 PubMed: 37952131
  9. Kidney outcomes trial
    Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes
    Perkovic V et al. (2024) · N Engl J Med.
    Direct Source DOI: 10.1056/NEJMoa2403347 PubMed: 38785209
  10. Registry record
    A Study in People With Obesity to Test the Effects of BI 456906 Compared With Semaglutide on Glucagon Receptor Activity in the Liver
    ClinicalTrials.gov (2026).
    Phase 1, active, not recruiting; 29 enrolled; sponsor Boehringer Ingelheim. Checked 11 October 2026.
    Direct Source
  11. Registry record
    A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE - CVOT)
    ClinicalTrials.gov (2026).
    Direct Source
  12. Registry record
    LIVERAGE: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis
    ClinicalTrials.gov (2026).
    Direct Source
  13. FDA safety communication
    FDA's concerns with unapproved GLP-1 drugs used for weight loss
    U.S. Food and Drug Administration (2026).
    Direct Source
  14. Official U.S. prescribing information
    Wegovy injection and tablets, current U.S. label
    DailyMed / National Library of Medicine (2026).
    Direct Source
  15. Official U.S. prescribing information
    Ozempic injection, current U.S. label
    DailyMed / National Library of Medicine (2026).
    Direct Source